Beyond Glucose: The Immunologic Architecture of Obesity and Type 2 Diabetes-Panel 2

Video Transcription

Video Summary

This episode of “Beyond Glucose” shifts from basic immunology to clinical care in obesity and type 2 diabetes. The panel explains that GLP-1 receptor agonists are not only powerful glucose- and weight-lowering drugs, but also likely anti-inflammatory agents that reduce CRP, increase adiponectin, and blunt pathways such as NF-kappa B, TNF-alpha, and NLRP3. They may help across multiple organs, including the heart, liver, kidneys, brain, and even inflammatory conditions like IBD and arthritis. The discussion also reviews other diabetes drugs: metformin and SGLT2 inhibitors have some anti-inflammatory effects, while TZDs are anti-inflammatory but can cause weight gain and fluid retention. Overall, the speakers emphasize a shift in guidelines toward weight-centric, patient-centered care, using multidisciplinary support, nutrition, exercise, sleep, and stress management to treat the whole person rather than glucose alone.

Keywords

GLP-1 receptor agonists

type 2 diabetes

obesity management

anti-inflammatory effects

weight-centric care

multidisciplinary treatment